Bone and Joint Infection, Dactinomycin Adverse Reaction
Conditions
Keywords
Eosinophilic pneumonia, Daptomycin, Bone and joint infection, Adverse event
Brief summary
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria. Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future
Detailed description
Daptomycin is an antibiotic from the family of cyclic lipopeptides, bactericide, concentration-dependent. Its spectrum concerns Gram-positive bacteria. The Infectious Diseases Society of America recommends the use of daptomycin 6 mg / kg / day in the second-line treatment of IOA on staphylococcal but also enterococcal prostheses, as an alternative to vancomycin and linezolid. In case of renal failure, daptomycin is often considered as a good therapeutic alternative to glycopeptides. Since the authorization of daptomycin in 2006, cases of eosinophilic pneumonia and pulmonary eosinophilia associated with its use have been reported in Europe and worldwide. Although a large proportion of cases have been reported in patients receiving daptomycin in unapproved indications, the use of daptomycin in authorized indications has also been associated with this risk. The dosage of daptomycin makes it possible to evaluate its effectiveness and prevent the occurrence of a overdose, provider of side effects. The purpose of this study is to describe the mechanism of occurrence of this AE with dapto; Prolonged exposure and accumulation at the alveolar level could potentially have a role. Better understanding the mechanisms of appearance of this AE would provide predictive elements making it possible to limit the occurrence of this AE in the future
Interventions
OTHERDescription of eosinophilic pneumonia due to daptomycine
Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Inclusion criteria
* patients having had an eosinophilic pneumonia under daptomycine given to treat an osteoarticular infection (BJI/PJI)
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| description of BJI/BJI in patients having eosinophilic pneumonia due to daptomycin | 2 months | description of the BJI/PJI (symptoms, type of evolution, type of implant) |
| description patients having eosinophilic pneumonia due to daptomycin | 2 months | description of the patients (average age, medical background) |
| rate of eosinophilic pneumonia due to daptomycin in osteoarticular infection: the adverse event | 6 months | number of cases and description of the adverse event as assessed by CTCAE v4.0 |
| Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: dosage of daptomycine | 6 months | description of the use of daptomycine : dosage |
| Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: duration of daptomycine | 6 months | description of the use of daptomycine : duration |
| Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: daptomycine plasma clearance | 6 months | mean daptomycine plasma clearance (unit, liters per hour) |
| Evalutation of eosinophilic pneumonia due to daptomycin in osteoarticular infection: daptomycine volume distribution | 6 months | mean daptomycine volume of distribution (unit, liters) |
Countries
France
Contacts
Primary ContactEugénie Mabrut, CRA
Backup ContactTristan Ferry, Md,PhD
Outcome results
None listed